Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Current Leases (2022 - 2025)

Caribou Biosciences (CRBU) has disclosed Current Leases for 4 consecutive years, with $2.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases rose 128.1% to $2.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.7 million, a 128.1% increase, with the full-year FY2024 number at $1.4 million, up 18.83% from a year prior.
  • Current Leases was $2.7 million for Q3 2025 at Caribou Biosciences, up from $2.3 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.7 million in Q3 2025 to a low of $825000.0 in Q1 2022.
  • A 4-year average of $1.3 million and a median of $1.2 million in 2024 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: grew 3.42% in 2024, then surged 128.1% in 2025.
  • Caribou Biosciences' Current Leases stood at $966000.0 in 2022, then increased by 24.22% to $1.2 million in 2023, then grew by 18.83% to $1.4 million in 2024, then skyrocketed by 88.43% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Current Leases are $2.7 million (Q3 2025), $2.3 million (Q2 2025), and $1.9 million (Q1 2025).